## RARE: Ultragenyx Pharmaceutical Inc. - XLV: Healthcare

### Executive Summary

STRENGTH thesis confirmed: MRS_20 at 5.1% in lower entry zone (4.0-10.0%), top quartile (75th pct) cross-sectional ranking. Short-term MRS_5 (1.4%) confirms momentum alignment. Outperforming sector by 5.4%.

- **Horizon:** 5-20 days (swing)
- **Risk Profile:** Moderate - momentum continuation
- **Stop Type:** Fixed 2xATR ($33.29)
- **If Wrong:** Exit if MRS_20 drops below entry zone or breaks stop
- **Invalidation:** MRS_20 exits entry zone or MRS_5 turns negative

### News

- **Articles:** 8
- **Sentiment:** Neutral (Bullish: 0, Bearish: 1)

**1. Frazier Life Sciences Management L.P. Acquires 325,000 Shares of Ultragenyx Pharmaceutical Inc. $RARE**
- Source: MarketBeat | 20251214T115120 | Somewhat-Bearish | Relevance: 100%
- Frazier Life Sciences Management L.P. significantly increased its stake in Ultragenyx Pharmaceutical Inc. by 49.3%, now holding 983,715 shares valued at approximately $35.77 million. This makes Ultragenyx its 17th largest position, despite the biopharmaceutical company missing recent quarterly earnings expectations and facing some analyst price target cuts. Institutional investors collectively own a substantial 97.67% of Ultragenyx's stock, though a CFO recently sold a portion of their holdings.

**2. Is Ultragenyx Pharmaceutical Inc. (RARE) One of the Best Biotech Stocks to Buy According to Wall Street Analysts?**
- Source: Insider Monkey | 20251211T120942 | Somewhat-Bullish | Relevance: 100%
- Wall Street analysts consider Ultragenyx Pharmaceutical Inc. (RARE) a strong biotech stock, with Citi and Cantor Fitzgerald reiterating Buy and Overweight ratings, respectively, and setting high price targets. Despite recent revenue and EPS shortfalls, the company reaffirmed its full-year guidance and strengthened liquidity through a Crysvita royalty sale. Analysts maintain confidence in Ultragenyx's long-term growth due to its focus on rare diseases and strategic use of assets.

**3. Ultragenyx Pharmaceutical (RARE): Reassessing Valuation After Recent Share Price Rebound**
- Source: Yahoo Finance | 20251214T140953 | Somewhat-Bullish | Relevance: 100%
- Ultragenyx Pharmaceutical's stock has rebounded by 10% in the past month, but its one-year return is still negative. Despite this, a "Most Popular Narrative" suggests the stock is 55.7% undervalued with a fair value of $81.85, attributing this to its advancing clinical pipeline and upcoming data readouts. However, persistent cash burn and potential regulatory delays pose risks to this optimistic valuation.

**4. Ultragenyx (RARE) CFO Horn sells $112k in stock**
- Source: Investing.com | 20251212T120916 | Somewhat-Bearish | Relevance: 100%
- Ultragenyx Pharmaceutical Inc. CFO Howard Horn sold 3,081 shares of common stock for $112,086 on December 10, 2025. The company, valued at $3.51 billion, has shown strong revenue growth but is not yet profitable. Analysts maintain a bullish consensus despite expected losses, and the stock currently appears undervalued.

**5. Insider Sell: Howard Horn Sells Shares of Ultragenyx Pharmaceuti**
- Source: GuruFocus | 20251211T200942 | Bearish | Relevance: 100%
- Howard Horn, CFO of Ultragenyx Pharmaceutical Inc (RARE), sold 3,081 shares on December 10, 2025, reducing his holdings to 95,146 shares. This transaction is part of a trend of 17 insider sales with no insider buys for the company over the past year. Based on its GF Value of $47.83, the stock, trading at $36.38, appears modestly undervalued.

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 0 ($0.00M) |
| Sells | 2 ($0.25M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 51.7% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 6 / 3 |

**Top Holders:**
- Vanguard Group Inc: 10.5% (-0.8%)
- JPMORGAN CHASE & CO: 8.3% (+146.0%)
- FMR, LLC: 7.6% (+179.6%)
- Blackrock Inc.: 6.7% (+2.7%)
- Sands Capital Manage: 3.9% (-4.4%)

### Key Risks

1. Elevated short interest (9.5%): bears positioning against stock.
2. Market regime shift could impact momentum names disproportionately.
3. Sector rotation risk if leadership changes from current market theme.

### Catalysts

- Broader market risk-on sentiment could lift quality names.
- Year-end positioning and window dressing may support price.

### Fundamentals

Revenue growth strong at 21% YoY. Institutional flow bullish (6 buying vs 3 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $3.5B |
| Beta | 0.16 |
| 52W Range | $25.81 - $46.75 |
| Short Interest | 9.5% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | -0.24 |
| Forward P/E | N/A |
| Current P/E | N/A |
| YoY Growth | N/A |
| EPS Direction | None |

### Technicals

MRS_20 weakening modestly (-0.9% over 5 days). Currently in lower STRENGTH zone (4.0-10.0%), cross-sectional ranking at 75th percentile. MRS_5 at 1.4% confirms short-term momentum alignment. AM_20 at 5.4% shows strong absolute momentum above own 20MA. Outperforming sector by 5.4pp, stock-specific strength. Full SMA alignment bullish (above 20/50/200 SMAs). OFD pattern: -SLN (Support test).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | 5.10% (CS: 76) | Strong |
| RSI_14 | 61.2 | Neutral |
| MACD Histogram | 0.18 | Bullish |
| vs SMA20 | 1.054x | Above |
| vs SMA50 | 1.084x | Above |
| vs SMA200 | 1.073x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** STRENGTH

### Trade Setup

- **Entry:** $36.23
- **Stop Loss:** $33.29 (8.1% risk)
- **Target:** $40.64 (R:R method)
- **Risk/Reward:** 1.50:1
- **Target Reasoning:** STRENGTH thesis targets 1.5x risk/reward based on historical edge

### Position Sizing

- **Shares:** 340
- **Position Value:** $12,318.20
- **Portfolio %:** 12.32%
- **Risk Dollars:** $1,000.00
- **Risk Per Trade:** 1.00%
- **Modifiers:** L1 100% | L2 100% | Combined 1.00x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | NEUTRAL (Zone E) | 1.00x |

*NORMAL regime with moderate risk appetite ahead of Fed decision. VIX remains calm at 15.74 while breadth shows modest participation at 54%, suggesting selective positioning. FOMC meeting in 4 days creates near-term uncertainty but no systemic stress evident.*

### Earnings

**Next:** 2026-02-12 (Est: $-1.23)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $-1.21 | $-1.81 | -49.7% |
| 2025Q2 | $-1.32 | $-1.17 | +11.4% |
| 2025Q1 | $-1.64 | $-1.57 | +4.4% |
| 2024Q4 | $-1.27 | $-1.39 | -9.4% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_20*